A Study of Cardiovascular Events iN Diabetes Plus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 21296 participants.

Also called NCT05441267

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 21,296 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05441267
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05441267. Randomized; quadruple masking; primary purpose prevention. Start 2023-03-13 (actual); primary completion 2028-08-17 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Cardiovascular Events iN Diabetes Plus
Acronym
ASCEND PLUS
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide Oral Tablet
Intervention (Drug)
Placebo oral tablet
Lead sponsor
University of Oxford (class: other)
Collaborator
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct05441267
Content hash
00d3819a2afca3b1d305e305312598e0275d13de25f39eccd555fa9565cce846